Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study.

被引：0
|
作者：
List, AF
Karanes, C
Dorr, R
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, J
Schiller, G
Dalton, W
Pearce, T
Litchman, M
机构：
[1] UNIV ARIZONA, TUCSON, AZ 85721 USA
[2] WAYNE STATE UNIV, DETROIT, MI 48202 USA
[3] VANDERBILT UNIV, NASHVILLE, TN 37240 USA
[4] DUKE UNIV, DURHAM, NC 27706 USA
[5] LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA
[6] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA
[7] SANDOZ, E HANOVER, NJ USA
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1156 / 1156
页数：1
相关论文
共 50 条
  • [41] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [42] Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
    Al-Ali, Haifa K.
    Jaekel, Nadja
    Junghanss, Christian
    Maschmeyer, Georg
    Krahl, Rainer
    Cross, Michael
    Hoppe, Gisa
    Niederwieser, Dietger
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 110 - 117
  • [43] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [44] HIGH-DOSAGE CYTOSINE-ARABINOSIDE AND MITOXANTRONE (HAM) IN REFRACTORY ACUTE MYELOID-LEUKEMIA (AML) - RESULTS OF A PHASE I/II STUDY
    HIDDEMANN, W
    KREUTZMANN, H
    STRAIF, K
    LUDWIG, WD
    FUHR, HG
    DONHUIJSENANT, R
    LENGFELDER, E
    BUCHNER, T
    BLUT, 1986, 53 (03): : 242 - 242
  • [45] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [47] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
    Stein, Eytan M.
    Dinardo, Courtney Denton
    Pollyea, Daniel Aaron
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    Flinn, Ian
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Stein, Anthony Selwyn
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Knight, Robert D.
    Agresta, Samuel V.
    De Botton, Stephane
    Tallman, Martin S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Oral Debio 1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study
    DiPersio, John F.
    Erba, Harry P.
    Larson, Richard A.
    Luger, Selina M.
    Tallman, Martin S.
    Brill, Jeffrey M.
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Sorensen, J. Mel
    Zanna, Claudio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 443 - 449
  • [49] A Randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using P-Glycoprotein (Pgp) modulation with valspodar (PSC833):: Preliminary results of cancer and leukemia group B study 19808.
    Kolitz, JE
    George, SL
    Marcucci, G
    Vij, R
    Powell, BL
    Allen, SL
    De Angelo, DJ
    Shea, T
    Stock, W
    Hars, V
    Hoke, E
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    BLOOD, 2005, 106 (11) : 122A - 123A
  • [50] Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML)
    Zeidner, Joshua F.
    Foster, Matthew C.
    Blackford, Amanda L.
    Litzow, Mark R.
    Morris, Lawrence E.
    Strickland, Stephen A.
    Lancet, Jeffrey E.
    Bose, Prithviraj
    Levy, M. Yair
    Tibes, Raoul
    Gojo, Ivana
    Gocke, Christopher D.
    Rosner, Gary L.
    Little, Richard F.
    Wright, John J.
    Doyle, L. Austin
    Smith, B. Douglas
    Karp, Judith E.
    LEUKEMIA RESEARCH, 2018, 72 : 92 - 95
12345